December 14th 2024
Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.
December 14th 2024
Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.
2 Commerce Drive
Cranbury, NJ 08512